Capricor Therapeutics CAPR Available For Sale Securities Debt Securities Current

Available For Sale Securities Debt Securities Current at other companies

PfizerPFE

——

Dyne Therapeutics, Inc.DYN

——

Viridian Therapeutics, Inc.VRDN

——

LeMaitre VascularLMAT

——

CytokineticsCYTK

——

Other financials

Income statement

See full

Revenue--100%

Operating income-$36.8M-47.2%

Net income-$33.9M-39.2%

EPS (diluted)-$0.59-11.3%

Balance sheet

See full

Cash & equivalents$105.4M+266%

Total debt$14.8M+1,083%

Total equity$278.7M+118%

Total assets$326.3M+112%

Cash flow

See full

Operating cash flow-$29.3M-355%

CapEx$5.1M+472%

Free cash flow-$34.4M-369%

Valuation

See full

Market cap$1.71B+303%

Profitability

See full

Operating margin-778.8%-1,038pp

Net margin-736.6%-981pp

FCF margin-563.9%-954pp

Returns & leverage

See full

Return on equity-56.4%-11.3pp

Debt / equity0.1×0.0×

Current ratio8.4×+1.9×

Where this comes from

Reported directly by Capricor Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent.

The official record: Capricor Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Capricor Therapeutics's available for sale securities debt securities current.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Capricor Therapeutics's available for sale securities debt securities current?: Capricor Therapeutics (CAPR) reported available for sale securities debt securities current of $173.19M in Q1 2026.